Pefloxacin mesylate CAS:70458-95-6

Pefloxacin mesylate is commonly prescribed for the treatment of respiratory tract infections, including pneumonia, bronchitis, and sinusitis, caused by susceptible pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Its ability to penetrate lung tissues effectively makes it suitable for combating lower respiratory tract infections. In the management of urinary tract infections (UTIs), pefloxacin mesylate is utilized to target uropathogens like Escherichia coli, Klebsiella species, and Proteus mirabilis. It is effective in treating complicated UTIs, pyelonephritis, and prostatitis due to its broad spectrum of activity. For skin and soft tissue infections such as cellulitis, abscesses, and wound infections, pefloxacin mesylate can be employed to combat susceptible bacteria present in these conditions. Its good tissue penetration properties enable effective treatment of localized infections. In cases of gastrointestinal infections or intra-abdominal infections like peritonitis and cholecystitis, pefloxacin mesylate can be administered to target enteric pathogens such as Salmonella, Shigella, and E. coli. Its broad spectrum of activity and high bioavailability make it a valuable option for managing complex abdominal infections. Adverse effects associated with pefloxacin mesylate therapy may include gastrointestinal disturbances, central nervous system effects like headache or dizziness, and rare but serious reactions such as tendon damage. Patients should be educated on proper medication use, potential side effects, and the importance of completing the full course of treatment to prevent resistance development. Healthcare providers play a critical role in prescribing pefloxacin mesylate appropriately, monitoring patients for optimal therapeutic outcomes, and ensuring patient safety during antibiotic therapy.